(Q33847395)

29 July 2017

1 reference

title

Palivizumab for respiratory syncytial virus prophylaxis (English)

1 reference

29 July 2017

Sandritter T

1

1 reference

29 July 2017

publication date

1 July 1999

1 reference

Journal of Pediatric Health Care

29 July 2017

published in

1 reference

29 July 2017

volume

13

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

191-5; quiz 196-7

1 reference

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Respiratory syncytial virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Humanized monoclonal antibody for prevention of respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2899%2990039-1

7 January 2021

10.1016/S0891-5245(99)90039-1

Identifiers

DOI

1 reference

29 July 2017

1 reference